Amalgamated Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Amalgamated Bank’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51K	Buy	13,885 +1,932	+16%	+$6.43K	﹤0.01%	1622
2026 Q1	$37K	Hold	11,953	–	–	﹤0.01%	1611
2025 Q4	$49K	Buy	11,953 +3,337	+39%	+$16.5K	﹤0.01%	1846
2025 Q3	$42K	Hold	8,616	–	–	﹤0.01%	1898
2025 Q2	$44K	Hold	8,616	–	–	﹤0.01%	1853
2025 Q1	$46K	Buy	8,616 +1,464	+20%	+$10.7K	﹤0.01%	1813
2024 Q4	$48K	Hold	7,152	–	–	﹤0.01%	1842
2024 Q3	$47K	Hold	7,152	–	–	﹤0.01%	1869
2024 Q2	$54K	Buy	7,152 +2,459	+52%	+$21.4K	﹤0.01%	1840
2024 Q1	$47K	Sell	4,693 -7,251	-61%	-$80.7K	﹤0.01%	1882
2023 Q4	$118K	Sell	11,944 -1,397	-10%	-$9.96K	﹤0.01%	1949
2023 Q3	$102K	Hold	13,341	–	–	﹤0.01%	1990
2023 Q2	$100K	Sell	13,341 -1,188	-8%	-$8.31K	﹤0.01%	2063
2023 Q1	$97K	Sell	14,529 -3,294	-18%	-$26.1K	﹤0.01%	2069
2022 Q4	$137K	Hold	17,823	–	–	﹤0.01%	2004
2022 Q3	$190K	Buy	17,823 +306	+2%	+$3.1K	﹤0.01%	1876
2022 Q2	$143K	Buy	17,517 +330	+2%	+$2.21K	﹤0.01%	2025
2022 Q1	$123K	Sell	17,187 -1,347	-7%	-$14.3K	﹤0.01%	2124
2021 Q4	$317K	Buy	+18,534	New	+$349K	﹤0.01%	1793

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Amalgamated Bank's RXRX Position: Q2 2026 in Review

Amalgamated Bank increased its Recursion Pharmaceuticals (RXRX) stake by 16% in Q2 2026, buying an estimated $6.43K and bringing the position to 13,885 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #1622.

Amalgamated Bank first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $317K in Q4 2021. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Amalgamated Bank held 13,885 shares of Recursion Pharmaceuticals worth $51K as of Q2 2026.
Amalgamated Bank bought 1,932 Recursion Pharmaceuticals shares in Q2 2026, an estimated $6.43K.
Recursion Pharmaceuticals made up ﹤0.01% of Amalgamated Bank's portfolio in Q2 2026, its #1622 holding.
Amalgamated Bank first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Amalgamated Bank's Recursion Pharmaceuticals position peaked at $317K in Q4 2021.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.